<DOC>
	<DOC>NCT01297400</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of MEBO in the treatment of subjects with partial thickness burns.</brief_summary>
	<brief_title>A Clinical Study of the Efficacy and Safety of MEBOÂ® Wound Ointment in Subjects With Partial Thickness Burns</brief_title>
	<detailed_description>MEBO-BPII-001 is a single-center, randomized, standard care-controlled pilot study of topically applied MEBO in subjects with partial thickness burns expected to heal in 14 days. Twice daily application of MEBO versus standard of care will be evaluated in a parallel design. Fourteen subjects will be randomized (7 subjects per treatment arm) to one of two treatment groups.</detailed_description>
	<mesh_term>Burns</mesh_term>
	<criteria>1. Male or female between 18 and 65 years of age. 2. Capable of giving informed consent. 3. Thermal origin burns. 4. Patients must be willing to comply with treatment application. 5. Capable of understanding and complying with study protocol requirements. 6. Study target burn area has had no previous surgical excision. 1. Chemical or electrical burns. 2. Patient with concomitant injury of head trauma, inhalation injury, or bone fracture. 3. Pregnant or breastfeeding female. 4. Known or suspected allergies to any of the components of MEBO. 5. Suspicion or presence of active systemic or local cancer or tumor of any kind. 6. Any immune deficiency disorder. 7. Suspected alcohol or drug abuse. 8. Participation in another investigational drug study within 30 days prior to treatment start.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Burns, Partial Thickness Burns</keyword>
</DOC>